Bright Minds Biosciences Inc. (DRUG)
Stock analysis · NASDAQ · Healthcare · Biotechnology
Bright Minds Biosciences Inc. (DRUG) is a publicly traded company in the Healthcare sector. Latest price: $54.98. Market cap $542.33M. Trailing PE -26.55. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.
Get full analysis → Short-Term Analysis →1-Year Price
Earnings
Proprietary Signals
About Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio includes 5-HT2 Receptors, which are serotonin agonists for epilepsy and neuropsychiatric disorders; and BMB-101, which has completed phase 1 trial for undisclosed seizure disorder and is in phase 2 clinical trials for the developmental and epileptic encephalopathies and absence epilepsies. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatric and neurology indications; and BMB-105, a 5-HT2C agonist to treat Prader Willi Syndrome. Bright Minds Biosciences Inc. has a collaboration with Firefly Neuroscience, Inc. to provide an analysis of the electroencephalogram (EEG) data in the Company’s BREAKTHROUGH study. The company was founded in 2017 and is headquartered in New York, New York.
Valuation
| P/E (TTM) | -26.55× |
|---|---|
| P/S (TTM) | 0.00× |
| P/B | 2.46× |
| PEG | 0.36× |
| P/FCF (TTM) | -30.42× |
| EV / EBITDA | -11.36× |
| EV / Sales | 0.00× |
| Earnings Yield | -3.27% |
| Free Cash Flow Yield | -3.29% |
Fundamentals
| Enterprise Value | $451.57M |
|---|---|
| Net Income (TTM) | -$24.80M |
| Free Cash Flow (TTM) | -$24.95M |
| Net Debt | -$307.96M |
| Working Capital | $308.11M |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
| Return on Equity | -12.56% |
| Return on Invested Capital | -12.92% |
Peers
Recent News
- CUMBERLAND PHARMACEUTICALS ANNOUNCES PLANS TO FILE NEW DRUG APPLICATION FOR IFETROBAN DMD PROGRAM
- Bright Minds Biosciences to Participate in the 2026 FPWR Research Symposium and PWS Family Conference
- Bright Minds Biosciences to Present at Upcoming Conferences
- What Makes Bright Minds Biosciences Inc. (DRUG) a Strong Momentum Stock: Buy Now?
- Wall Street Analysts See a 97.01% Upside in Bright Minds Biosciences Inc. (DRUG): Can the Stock Really Move This High?
Related
Browse more tickers: sitemap